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Abstract
Background: To use amifostine concurrently with radiochemotherapy (CT-RT) or radiotherapy
(RT) alone in order to prevent dry eye syndrome in patients with malignancies located in the
fronto-orbital region.
Methods: Five patients (2 males, 3 females) with diagnosed malignancies (Non-Hodgkin B-cell
Lymphoma, neuroendocrine carcinoma) involving the lacrimal gland, in which either combined CT-
RT or local RT were indicated, were prophylactically treated with amifostine (500 mg sc). Single
RT fraction dose, total dose and treatment duration were individually adjusted to the patient's
need. Acute and late adverse effects were recorded using the RTOG score. Subjective and
objective dry eye assessment was performed for the post-treatment control of lacrimal gland
function.
Results: All patients have completed CT-RT or RT as indicated. The median total duration of RT
was 29 days (range, 23 – 39 days) and the median total RT dose was 40 Gy (range, 36 – 60 Gy).
Median lacrimal gland exposure was 35.9 Gy (range, 16.8 – 42.6 Gy). Very good partial or complete
tumor remission was achieved in all patients. The treatment was well tolerated without major toxic
reactions. Post-treatment control did not reveal in any patient either subjective or objective signs
of a dry eye syndrome.
Conclusion: The addition of amifostine to RT/CT-RT of patients with tumors localized in orbital
region was found to be associated with absence of dry eye syndrome.
Background
Xerostomia, mucositis and dysphagia are known serious
adverse reactions associated with radiotherapy (RT) or
radiochemotherapy (CT-RT) of tumors localized in the
head and neck region. Of particular concern is xerosto-
mia, which develops acutely, but persists chronically after-
wards and may lead to serious complications. Another
serious toxic reaction to RT is xerophthalmia (dry eye syn-
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drome/keratoconjunctivitis sicca), which can develop
after local irradiation of the fronto-orbital region and can
lead to severe visual impairment. Generally, the burden
caused by RT-induced toxic reactions is not only detri-
mental for the patient's quality of life and the compliance
with treatment, but may also have considerable phar-
maco-economic consequences because of the costs
incurred by loss of productivity, hospitalization and, fre-
quently, expensive supportive measures [1]. It is therefore
a major and desirable goal of the RT to achieve tumor
remission without compromising the general well-being
of the patient.
Amifostine is a unique drug selectively protecting non-
affected tissues from CT-RT induced toxicity. Its efficacy in
preventing toxic damages induced by irradiation of
tumors localized in the head and neck region, particularly
in the naso-oropharynx, has been demonstrated in several
clinical trials [2-7].
We report here our experience with amifostine, which was
used as a prophylactic measure during RT of malignant
tumors localized in the fronto-orbital region, involving
the ipsilateral lacrimal gland.
Methods
Patient sample
Five Patients, who were admitted to the department of
radiation oncology, Inselspital Bern with histopathologi-
cally characterized unilateral malignant tumors of the
orbital region and who gave informed consent for treat-
ment with RT or CT-RT combined with amifostine, where
included in this study. None of the patients had a history
of dry eye, sarcoidosis, or thyroid associated eye disease.
Treatment
According to the diagnosis and histopathological findings
for each patient a 3D RT planning was performed. Using
dose volume histograms (DVH) minimum and maxi-
mum dose exposure of the lacrimal gland was deter-
mined. Two patients received chemotherapy according to
the standard CHOP-protocol. In one patient, chemother-
apy preceded RT and in another it was given concurrently
with RT.
Amifostine in a dose of 500 mg was given subcutaneously
30 min prior to each RT-fraction to all patients
Lacrimal gland assessment
In order to check for possible existence of dry eye syn-
drome in the post – treatment period lacrimal gland func-
tion was systematically assessed in all patients. The
objective ophthalmic tests were performed at different
time intervals after the termination of RT. The longest
interval between RT and the tests was 88 weeks (pat. No
4) and the shortest 9 weeks (pat. No 5), median interval
was 57.5 weeks.
The following objective tests were performed: a) Schirmer
I (with and without local anesthesia), which measures
basic and reflex-secretion of the lacrimal gland, b)
Schirmer II (nasal stimulation) test, which measures stim-
ulated secretion of the lacrimal gland c) Tear-film break
up time (BUT), which measures the time of onset of a ran-
dom appearance of the first black spots on the cornea after
one single palpebral (eyelid-blinking) closure under
standardized conditions, d) corneal and conjunctival flu-
orescein staining and e) Rose bengal staining of the con-
junctiva.
A single examiner performed all of the tests and interviews
during the examination in the department of ophthalmol-
ogy. In all tests of the non-irradiated, contralateral eye
served as control except in patient 1. The procedures are
briefly described below.
Dry eye symptom questionnaire
Patients were first interviewed to survey the frequency of
occurrence of various dry eye symptoms including dry-
ness, grittiness, redness, excess tearing or watery eyes, sen-
sitivity (to smoke, wind, air conditioning) and soreness.
Response categories used for analyses included never, sel-
dom (two to three times per week), often (four to five
times per week), and always (everyday).
Schirmer I test
The Schirmer I test (Laboratoires H. Faure, Annonay,
France) was performed without anesthetic (5 min, open
eye) and the strip was placed over the inferior lid margin
towards the lateral canthus. Abnormal values were
defined as < 5 mm in 5 min for the Schirmer test. Baseline
secretion is determined essentially as described above,
except that the eye is anesthetized 2 minutes before the
exam with one drop of local anesthetic (Novocaine 2%,
Inselspital, Bern).
Schirmer II test
The procedure is similar to Schirmer I test, except that after
the suspension of the paper strip in the inferior fornix of
a non-anaesthetized eye, the nasal mucosa is stimulated
for 2 minutes with a cotton tip frotting on the nasal
mucosa between the concha medalis and the concha infe-
rior [8].
Tear-film break up time (BUT)
The tear-film break-up time measurement was taken using
the cobalt blue illumination on the slit-lamp and a 3 mm
wide scanning beam in each eye. Fluorescein sodium was
instilled on the inferior palpebral conjunctiva using a Flu-
orescein Ophthalmic Strip (Haag-Streit, Köniz, Switzer-Radiation Oncology 2008, 3:22 http://www.ro-journal.com/content/3/1/22
Page 3 of 6
(page number not for citation purposes)
land). The latency to the first, random appearance of a
black spot, in the otherwise yellow-green colored surface
of the eye after complete closure of the eye-lid, is meas-
ured. The normal latency to the first black-spot appear-
ance is 15 – 35 sec and the values below 10 indicate an
insufficient lubrification of the corneal surface.
Corneal and conjunctival fluorescein staining
Fluorescein sodium was instilled on the inferior palpebral
conjunctiva using a Fluorescein Ophthalmic Strip (Haag-
Streit, Köniz, Switzerland). Following instillation of fluo-
rescein, the patient was instructed to blink several times.
The slit-lamp cobalt blue was used in the assessment of
tear break-up time and fluorescein staining to enhance the
appearance of the fluorescein. Staining was recorded for
the cornea and the conjunctiva. The cornea and adjacent
exposed bulbar conjunctiva was graded using a 0–3 scale
resulting in a total staining score. Abnormal staining (flu-
orescein and rose bengal) was classified as greater than or
equal to a score of 3 [9].
Rose bengal staining of the conjunctiva
Rose bengal staining of the conjunctiva was performed by
using a Rosets TM Rose Bengal Ophthalmic Strip (Chau-
vin Pharmaceuticals Ltd, Brentwood, UK) wetted with
non-preserved buffered saline and instilled on the inferior
bulbar conjunctiva. Grading for rose bengal staining was
described previously [9]. A score 3 or higher was consid-
ered pathological [10].
Adverse events
Acute and late adverse effects were recorded using the
Radiation Therapy Oncology Group (RTOG) score http://
www.rtog.org/members/toxicity/late.html. Spontane-
ously reported signs of eye discomfort such as for instance
tears, redness or dryness of the eye, were regularly
recorded. It is to note, that there were no subjective or
objective signs of eye discomfort in any patient prior to
CT-RT or RT.
Results
Patients characteristics
Demographic characteristics of patients are presented in
Table 1. Incisional histopathology confirmed malignant
tumors of different tumor entities (Non-Hodgkin B-Cell
Lymphoma, n = 4; neuroendocrine carcinoma, n = 1) with
expansion into the orbita. Two patients were male, three
were female, median age was 63 years (range, 28 – 79
years).
Clinical outcome
Table 2 illustrates the details of the treatment modalities
and the outcome of treatment in each patient. Combined
CT-RT was given in two and RT alone to 3 patients. The
median RT treatment period was 29 days (range, 23 – 39
days). The median total RT dose applied to the reference
point according to the International Comission on Radia-
tion Units and Measurements (ICRU) 10 was 40 Gy
(range, 36 – 60 Gy). Median lacrimal gland exposure on
the treated side was 35.9 Gy (range, 16.8–42.6 Gy). All
patients completed the treatments according to the
planned protocol. In all patients the response to therapy
was excellent with complete response in 2 patients and a
partial remission in the remaining three patients.
A brief description of the histories is given below.
Patient No 1
Presented himself with progressive protrusion of his left
eye, anosmia and difficulties with nasal breathing. CT and
MRI examinations showed a frontobasal tumorous for-
mation with extension from frontal sinus to sphenoidal
sinus with protrusion to orbital and nasal cavity. There
were also large osseous destructions of the lamina cribrosa
and the medial orbital and maxillar sinus walls. His-
topathological findings confirmed the diagnosis of a
malignant neuroendocrine small cell carcinoma in
advanced stage.
The patient was hospitalized and sequential CT-RT initi-
ated. He was treated according to the CHOP-protocol
with a good and rapid response after 1 cycle. Radical,
frontobasal radiotherapy with a total dose of 60 Gy,
Table 1: Characteristics of the patient sample
Clinical factors
Pat No Gender Age Diagnosis Tumor localization
1 Male 28 Neuroendocrine carcinoma Frontobasal part of the right nasal sinus
2 Female 60 Non-Hodgkin B-cell Lymphoma, low grade (St. IAE) Right lacrimal gland
3 Female 69 Non-Hodgkin B-cell Lymphoma, low grade, (St. IAE; Malt-Type) Right orbita
4 Female 63 Non-Hodgkin-B-cell Lymphoma, high grade, (St. IAE) Right M. temporalis, with orbital expansion
5 Male 79 Non-Hodgkin B-cell Lymphoma, low grade, (St. IAE) Right palpebra
Abbreviations: St. = stage; IAE = staging according to the Ann-Arbor-classification; M. = musculusRadiation Oncology 2008, 3:22 http://www.ro-journal.com/content/3/1/22
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applied simultaneously with the first and second out of
totally six cycles of chemotherapy with Cisplatin 60 mg iv
and Etopophos 240 mg iv led to almost complete regres-
sion of the tumorous tissue.
In the course of the RT the patient developed an acute
grade II enoral mucositis, conjunctivitis and rhinitis,
which regressed without further consequences after topi-
cal treatment.
Patient No 2
Underwent surgical intervention and subsequent external
beam RT (total dose 50 Gy) of the Th-3-5 region because
of metastatic, epidural tumors with compression of the
spinal cord. 3 years later she presented herself again for
consultation because of a massive palpebral edema, ptosis
and exophthalmus of the right eye. Histopathological
findings confirmed the diagnosis of a low-grade Non-
Hodgkin B-Cell Lymphoma, stage IAE, with orbital expan-
sion. A RT was performed with a total dose of 36 Gy. There
were no toxic reactions found. One and a half year later
the patient was in complete remission.
Patient No 3
Suffered from a progressive exophthalmus in her right eye
for several years. The MRI showed an expansive tumorous
mass in the right orbital cavity with intracranial spreading.
Histopathologically findings confirmed the diagnosis of a
Non-Hodgkin B-Cell Lymphoma, stage IAE, from the
mucosa associated lymphatic tissue (MALT) type. Local
radiotherapy of the right orbital region was performed to
a total dose of 40 Gy. 27 weeks later the patient showed a
complete remission of the tumor.
Radiotherapy was well tolerated. The only adverse reac-
tions were grade I – skin reactions, a mild transitory con-
junctivitis and a localized alopecia without consequences.
Patient No 4
Presented herself for a progressive edema in the right tem-
poral region. A biopsy revealed a diffuse Non-Hodgkin B-
Cell Lymphoma, stage IAE, with infiltration of the tempo-
ral muscle and expansion into the orbit. CHOP-protocol
was initiated and completed in 3 cycles. Additionally, she
received local external beam RT of the temporal region for
consolidation with a total dose of 46 Gy
Until the end of the RT, except for a mild skin erythema,
no other toxic reactions or complications were found.
However, after 7 applications of amifostine (12 days after
the start of RT) an allergic reaction to amifostine devel-
oped in the form of a generalized skin rash and edema of
the face and neck. After stopping amifostine, the patient
recovered without consequences. The post RT-control of
the patient showed partial remission of the tumor.
Patient No 5
Presented himself with a progressive, persistent edema of
the right eyelid, which had started 3 years ago. Histopa-
thology confirmed the diagnosis of a low grade Non-
Hodgkin B-Cell Lymphoma, stage IAE. Local RT of the
right palpebral region was performed to a total dose 36
Gy.
There were no major toxicities during the RT treatment.
Mild skin erythema of the right eyelid was the only
adverse reaction. The post RT-control of the patient
showed partial remission of the tumor.
Adverse reactions
As seen from the case histories there were no major toxic-
ities during the RT treatment and only few, mostly mild
and transitory adverse events were recorded. One patient
however showed, an allergic reaction to amifostine with
generalized skin rash and edema of the face and neck
which disappeared after halting amifostine.
Post-treatment ophthalmologic control
The ophthalmic exams were performed at different time
intervals after the termination of RT. The longest interval
between finished RT and the exams was 88 weeks (pat. No
4) and the shortest 9 weeks (pat. No 5). The results of the
post treatment-control of lacrimal gland function are
illustrated in Table 3. As seen there were no clinically rel-
Table 2: Treatment modalities and outcome
Treatment factors
Pat No Radio chemotherapy CT/RT* RT (total duration days) Total RT Dose† Gy Median RT dose Lacrymal gland Gy 
right/left
Clinical Outcome
1 6/39 60 16.8/16.5 partial remission
2 35 36 35.9/0 complete remission
3 29 40 42.6/5.4 complete remission
4 3/34 46 35.4/0 partial remission
5 23 36 36.3/0.54 partial remission
*CT = chemotherapy; RT = radiotherapy; CT/RT = total cycles/total duration days; † for the RT reference pointRadiation Oncology 2008, 3:22 http://www.ro-journal.com/content/3/1/22
Page 5 of 6
(page number not for citation purposes)
evant impairments of glandular function, which would
indicate serious dry-eye syndrome. Seldom feeling of a
dryness of the exposed eye (n = 1), often tears (n = 1) and
often eye-burning (n = 1) were the only subjective and
reported complaints.
Discussion
Selective protective effects of amifostine against RT
induced side effects localized in various body organs
(lungs, rectum, cervix, ovaries) have been demonstrated
in numerous clinical trials [6]. Its efficacy in patients with
malignancies located in the head and neck region is, how-
ever, of particular importance. Ionizing radiation of this
region impairs salivary and lacrimal gland functions,
which has acute and long-term consequences for the
patient. Proper lubrification of oral mucosa is a physio-
logical prerequisite for normal chewing, swallowing,
speaking, dental health and, last but not least, sleep
[11,12]. Dryness of the eye, besides the discomfort, may
lead to severe visual impairment due to the corneal dam-
age. One study has reported the occurence of mild dry eye
syndrome in 21% of patients after radiotherapy for stage
IAE orbital lymphoma after a total dose of 30–51 Gy [13].
However in this study no dose volume histogram analysis
for dose exposure of the lacrimal gland was performed
and the data is thus not directly comparable to our study.
The experience with amifostine in patients with head and
neck cancer is at present based on several studies. In a
large (N = 315), randomized, comparative trial in patients
with predominantly (≥75%) parotid gland carcinoma,
Brizel et al. [5] have shown that by comparison to RT
alone the concurrent amifostine-RT treatment reduced the
overall incidence of grade ≥2 xerostomia from 78% to
51%. In another comparative study in 50 patients with
mainly naso-oro-pharyngeal tumor localization, Antona-
dou et al. have shown considerable reduction of acute
(mucositis and dysphagia) and late (xerostomia) RT-tox-
icities in the amifostine treated group (n = 22). In the con-
trol group 73.9% of patients (n = 23) developed grade 2
xerostomia, whereas in the amifostine-RT group there
were only 27.2% patients with mild grade 2 xerostomia.
Similar results were also reported in an earlier trial by
Büntzel et al. In none of these studies amifostine treat-
ment compromised the outcome of RT. In contrast, by
comparison to the controls, the tumor remission rate in
amifostine treated patients was, as a rule, higher (up to
90%) [14-16]. To the best of our knowledge, no clinical
reports with amifostine in protecting lacrimal gland func-
tion from the irradiation of the orbital region have been
reported.
In a rabbit model Beutel et al. evaluated the effect of ami-
fostine in the tear gland and found morphological and
functional evidence of its radioprotective properties [17].
Even though limited to five patients only, our observation
is suggesting high success of combined amifostine-RT-
treatment regarding tumor remission. Two out of five
patients have achieved complete remission and the
remaining three a partial remission of the tumors. Further,
none of the patients experienced any major toxic reaction
to RT. In particular, neither subjective complaints nor
objective findings of the post-treatment ophthalmologic
tests have revealed signs of a dry-eye syndrome.
As a matter of fact, we can not exclude the possibility that
the lacrimal gland in our patients was exposed to a insuf-
ficiently high irradiation dose to induce any serious func-
tional damage of the gland. Systematic investigations of
the irradiation dose-effect relationship in cases of orbital
tumors have not yet been done. In his review about the
tolerance of the normal tissue to therapeutic radiation
Emami [18] refers to the experiences related to the eye and
parotid gland exposure to radiation. These observations
seem to suggest a very steep dose-response curve at least
for the eye. The quoted study of the exposure of the retina
to 45–50 Gy led to detectable damages and that of 65 Gy
and more to visual loss. For the parotid gland his estimate
of the tolerance dose (TD) 5/5 (normal tissue complica-
tion probability at 5% within 5 years after radiotherapy),
based on the reviewed studies was 32 Gy.
Table 3: Post-treatment lacrimal gland function
Opthalmologic tests
Pat No Follow-up time 
(weeks after RT)
Schirmer I with 
anesthetic OD/OS
Schirmer I (without 
anesthetic) OD/OS
Schirmer II (nasal 
stimulation) OD/OS
BUT OD/OS staining score
1 57.5 35/35 10/9 2/8 10/10 1 (OS)
2 77 5/10 5/7 7/11 15/15 1 (OD)
3 27 19/11 24/25 17/17 4/9 1 (OD)
4 87.7 5/18 1/7 9/17 15/15 2 (OD)
5 8.7 20/10 17/10 not performed 6/6 0
Abbreviations: RT = radiotherapy; OD = right eye; OS = left eye; BUT = break up timePublish with BioMed Central    and   every 
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Conclusion
Our results indicate that the addition of Amifostine to RT-
/CH-RT in patients with tumors localized in orbital region
is safe and associated with absence of dry eye syndrome.
Our data encourage further studies of concurrent amifos-
tine therapy.
This result is in accordance with the results of other clini-
cal studies showing radioprotective effect of amifostine in
patients with malignancies located in the head and neck
region and radiation exposure involving the parotid
gland.
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